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 Microglia, major glia of the central nervous system
(CNS), play a critical role as resident immunocompetent and
phagocytic cells in the CNS [1]. Presence of activated micro-
glia was demonstrated in pathological lesions in several neu-
rological and retinal diseases including Alzheimer’s disease,
Parkinson’s disease [2], multiple sclerosis [3] and retinal de-
generation [4,5]. Although microglia promoted neuronal cell
viability and survival by producing growth factor and remov-
ing potentially toxic cellular debris [6], there was also evi-
dence that activated microglia was deleterious to neurons
through excessive production of inflammatory mediators [5,7].
Microglia and their secretions were major contributors to the
enhanced death of neurons in neurodegenerative diseases [8].
Hence, understanding the secretion of microglia and the mecha-
nisms regulating microglial activation is an important step in
developing therapeutic strategies that ameliorate symptoms
of these diseases. Studies demonstrated that brain-derived
microglial cells released immuno-regulatory and
neuroprotective agents in interaction with phosphatidyl serine-
expressing apoptotic cells [9]. However retinal microglial cells
promoted photoreceptor death in vitro [10,11]. Previous stud-
ies mainly reported the expression of cytokines/chemokines
in brain microglia, which was different from retinal micro-
glia. In this study the cultured retinal microglia was used to
study microglial activity. Lipopolysaccharide (LPS) is used
as a tool to simulate a challenge by gram-negative bacteria
and to study the microglial activation process.
Minocycline, a semi-synthetic, long-acting tetracycline
derivative with good penetration of the blood-brain barrier,
has recently been shown to have remarkable neuroprotective
properties in models of neurodegeneration [12,13], brain is-
chemia [14], and multiple sclerosis [15]. Aside from its direct
anti-apoptosis effect, this neuroprotective function was also
associated with reduced activation of microglia and reduction
of inducible nitric oxide synthase (iNOS) and interleukin-1β
(IL-1β)-converting enzyme (ICE) expression [4,14]. However,
the mechanism regulating this inhibition was not clear.
Sulforaphane, a naturally occurring cancer
chemopreventive agent found in broccoli [16], has been shown
to suppress LPS-mediated expression of iNOS, Cox-2 and
tumor necrosis factor-α (TNF-α) in Raw 264.7 macrophage
cells [17]. In view of this observation, we hypothesized that
sulforaphane may modulate the inflammatory response of ac-
tivated retinal microglia. Because sulforaphane occurs natu-
rally in the widely consumed vegetable broccoli, this might
provide a convenient approach to militate retinal degenera-
tive diseases.
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Purpose: To elucidate the inhibitory effect of minocycline and sulforaphane on lipopolysaccharide (LPS)-induced retinal
microglial activation and the mechanisms through which they exerted their inhibitory effects.
Methods: Primary retinal microglial cultures were exposed to LPS with or without minocycline and sulforaphane. The
mRNA expression of monocyte chemotactic protein (MCP)-1, MCP-3, macrophage inflammatory protein (MIP)-1α,
MIP-1β, eotaxin, regulated upon activation normal T-cell expressed and secreted (RANTES) protein, and interleukin
(IL)-10 were examined by reverse transcription polymerase chain reaction (RT-PCR) assay. The mRNA expression of
inducible nitric oxide synthase (iNOS) and subsequent nitric oxide (NO) production were examined by RT-PCR assay and
Griess reagent assay. Protein expression of the p65 subunit of nuclear factor-κB (NF-κB) and p-p38, p-p44/42 and p-JNK
mitogen-activated protein kinases (MAPKs) were examined by Western blot and immunofluorescent analysis.
Results: Cultured retinal microglial cells were activated following exposure to LPS. The mRNA expression and protein
production of eotaxin, RANTES, and IL-10 and the mRNA expression of iNOS and subsequent NO production were
upregulated. The protein expression of p-p38, p-JNK, and the p65 subunit of NF-κB were also upregulated. However, the
protein expression of p-p44/42 was not significantly changed. Pretreatment with minocycline or sulforaphane for 1 h
before LPS administration inhibited LPS-induced microglial morphological change and inhibited LPS-induced upregulation
of p-p38, but had no effect on the expression of p-p44/42, p-JNK, and the p65 subunit of NF-κB.
Conclusions: Minocycline and sulforaphane inhibited LPS-induced retinal microglial activation, Western blot and immu-
nofluorescent studies showed decreased p-p38 MAPK expression. We suggested that the inhibitory effect of minocycline
and sulforaphane was partly through a p38 MAPK-dependent mechanism.
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1083In the present study, we investigated (1) the expression of
immunological signaling molecules in cultured retinal micro-
glia with or without LPS treatment; (2) the cellular pathways
regulating the LPS-mediated microglial activation processes;
and (3) the inhibitory effect of minocycline and sulforaphane
on LPS-mediated microglial activation and the mechanisms
through which they exert their effects.
METHODS
Primary retinal microglial culture:  A primary culture of mu-
rine retinal microglial cells was prepared from newborn
Sprague-Dawley rat retinas according to the technique by
Roque and Caldwell [18], with minor modifications. Briefly,
the eyes were enucleated and dissected, the retinas were peeled
out and incubated in Ca++/Mg++-free Hank’s balanced salt so-
lution containing 0.25 mg/ml trypsin and 0.4 mg/ml EDTA at
37 °C for 20 min (Sigma-Aldrich, St. Louis, MO). Afterwards,
enzyme-treated tissues were dissociated into single cells by
gentle pipetting and centrifuged. The dissociated cells were
resuspended in DMEM/F-12 (1:1; Invitrogen Corporation,
Grand Island, NY, USA) containing 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin (Sigma-Aldrich). Cells
were seeded at a density of 106 cells/ml in T75 culture flasks
(Corning Incorporation, Corning, NY) and incubated at 37 °C
in a humidified atmosphere of 5% CO2 and 95% air. After 2-3
weeks in vitro, microglial enriched cultures were shaken at
200 rpm on an orbital shaker (Lab-Line Instruments, Melrose
Pk, IL) for 4 h and harvested. Microglial cells were reseeded
in poly-L-lysine-coated 35 mm culture dishes (Corning In-
corporation, Corning, NY).
Immunofluorescent studies:  For immunofluorescence, the
cultures were fixed with 4% paraformaldehyde in 0.01 M phos-
phate-buffered saline (PBS) for 30 min and rinsed with PBS.
The cells were permeabilized with cold (-20 °C) methanol for
10 min. After washing with PBS, they were incubated with
blocking buffer (1% bovine serum albumin) for 3 h at room
temperature. Subsequently, the cultures were incubated with
primary antibodies to microglia (CD11b, Serotec Ltd., Ox-
ford, UK), astrocytes (GFAP, Santa Cruz Biotechnology, Santa
Cruz, CA), Müller cells (CRALBP, Santa Cruz Biotechnol-
ogy), the p65 subunit of NF-κB (Santa Cruz Biotechnology,
Santa Cruz, CA), and the p-p38, p-p44/42, and p-JNK mito-
gen-activated protein kinases (MAPKs; Promega Corporation,
Madison, WI) overnight at 4 °C. After rinsing with PBS, the
cultures were incubated with the appropriate secondary anti-
bodies for 45 min and examined by fluorescent microscopy.
Cell exposure experiment:  1. Activation of microglia with
LPS: Harvested microglial cells were seeded onto 35 mm cul-
ture dishes (Corning Incorporation, Corning, NY) and allowed
to grow for 2 days. After three washes with PBS, they were
incubated with serum-free medium (Invitrogen Corporation,
Grand Island, NY) containing 200 ng/ml LPS (Sigma-Aldrich)
[19]. The cultures were exposed for 24 h unless otherwise
stated.
2. Treatment with pharmaceutical agents: In some experi-
ments, microglial cultures were exposed to minocycline
(Sigma-Aldrich, St. Louis, MO), sulforaphane (LKT labora-
tories, St. Paul, MN), or SB203580 (a specific inhibitor of
p38 MAPK, Sigma-Aldrich) for 1 h before administering LPS.
To determine a dose-response curve for different concentra-
tions of minocycline on the extent of LPS stimulation, the
cultures were treated with 2.5 µM, 0.625 µM, 0.16 µM, 0.04
µM, 0.01 µM, and 0.0025 µM minocycline for 1 h and then
exposed to LPS. To determine a dose-response curve for dif-
ferent concentrations of sulforaphane on the extent of LPS
stimulation, the cultures were treated with 80 µM, 40 µM, 20
µM, 10 µM, 5 µM, 2.5 µM, 1.25 µM, and 0.32 µM
sulforaphane for 1 h and then exposed to LPS. Minocycline
was dissolved in PBS and diluted with serum-free medium.
Sulforaphane and SB203580 were dissolved in dimethyl sul-
foxide (DMSO, Sigma-Aldrich) and diluted with serum-free
medium before addition to the microtiter plate well. The final
concentrations of DMSO were less than 0.1% (by volume).
Nitric oxide and cytokine assays:  The production of ni-
tric oxide (NO) was quantified by measuring the released NO
metabolites (nitrate and nitrite) with Griess reagent (Sigma-
Aldrich). The culture media samples were collected and pre-
pared cell-free by centrifugation. The media (100 µl) were
incubated with the same volume of Griess reagent at room
temperature for 15 min, and were measured at 570 nm in a
microplate reader (Bio-Rad, Richmond, CA) with an appro-
priate standard. The Griess reagent assays were repeated four
times.
Monocyte chemotactic protein (MCP)-1, MCP-3, mac-
rophage inflammatory protein (MIP)-1α, MIP-1β, eotaxin,
regulated upon activation normal T-cell expressed and secreted
(RANTES) protein, and interleukin (IL)-10 samples were pre-
pared similar to NO samples and determined using rat ELISA
Kits (R&D Systems, Minneapolis, MN) according to
manufacturer’s instructions. These experiments were repeated
four times.
Total RNA extraction and semi-quantitative reverse tran-
scription:  The microglial cells were exposed to LPS with or
without minocycline or sulforaphane for 1 h, 4 h, 12 h, or 24
h, and harvested. For PCR assay, the cells were plated in 6-
well plates with 2x106 cells per well. Total RNA was extracted
using the Trizol reagent (Invitrogen Corporation) according
to the manufacturer’s instructions. Reverse transcription (RT)
was performed with oligonucleotide primers using Superscript
reverse transcriptase (Invitrogen Corporation) according to the
manufacturer’s protocol and PCR was performed afterwards.
The primers and annealing temperatures are shown in Table
1. Each PCR product was separated on 2% agarose gel and
analyzed with Quantity One 1-D Analysis software (Bio-Rad).
The amount of RT-PCR product was corrected with β-actin
expression. Experiments with series diluted template amplifi-
cation for 30-35 cycles were just in the linear range of detec-
tion of the examined genes, so we chose to amplify all exam-
ined genes for 35 cycles. The level of expression was com-
pared within the time course for one particular gene. In each
series of experiments (between 0 to 24 h), the highest expres-
sion was arbitrarily normalized to 100%. The PCR experi-
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1084ments were repeated four times from separate cultures.
Western blot analysis:  The microglial cells were exposed
to LPS with or without minocycline or sulforaphane for 1/3 h,
1/2 h, 1 h, or 2 h, and harvested. For Western blot assay, the
cells were plated in 6-well plates with 2x106 cells per well.
Proteins were extracted using protein lysis buffer (50 mM Tris-
CL pH 8.0, 0.02% sodium azide, 1 µg/ml aprotinin, 1% NP-
40, 100 µg/ml phenylmethylsulfonyl fluoride [PMSF]) and
the final protein concentrations were determined using the BCA
protein assay kit (Pierce Biotechnology, Rockford, IL) accord-
ing to the manufacturer’s specifications. Western blot analy-
sis was then performed as previously described [20]. The an-
tibodies to the p65 subunit of NF-κB, to p-p38, p-p44/42 or p-
JNK MAPKs (1:1000 dilution in blocking solution) were used
for immunodetection. In some cases, an anti-ERK2 MAPK
polyclonal antibody was used to assay total (phospho-inde-
pendent) ERK and served as a control to ensure that equiva-
lent quantities of proteins were used for SDS-PAGE. To evalu-
ate other proteins, the blot was stripped in stripping buffer
(62.5 mM Tris-CL pH 6.8, 2% SDS, 100 mM β-
mercaptoethanol) for 30 min at 50 °C and re-probed. The west-
ern blot experiments were repeated four times from separate
cultures.
Statistical analysis:  Data were presented as the mean±SD.
Statistical comparisons were made by single-factor ANOVA.
p<0.01 was considered significant.
RESULTS
Characterization of mouse retinal microglial cells:  The mi-
croglial cells were harvested from 14-day-old primary mixed
glial cell cultures (Figure 1A) with a “shaking off” method
[18]. After purification, cells developed the characteristic rami-
fied shape of resting microglia with a long single process and
a small cell soma (Figure 1B). More than 95% of the purified
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TABLE 1. OLIGONUCLEOTIDES USED FOR REVERSE TRANSCRIPTION
POLYMERASE CHAIN REACTION
                                                           Annealing
                                                          temperature
Target gene         Sequences (5'-3')        Location        (°C)
-----------   ---------------------------   -----------   -----------
β-Actin       F: CATCCTGCGTCTGGACCT         NT 603-1082        59
              R: TCAGGAGGAGCAATGATCTTG
MCP-1         F: ACTGGACCAGAACCAAGTGAGA     NT 342-666         61
              R: TGTTGAACCAGGATTCACAGAGA
MCP-3         F: GGTTGAGGAGGCCATAGCATAC     NT 329-705         61
              R: CACTGATTCTTGCAATGTCCCT
MIP-1α        F: GAGCTGGAACTAAATGCCTGA      NT 328-653         61
              R: TCACCAAACACAGTGTGAGCA
MIP-1β        F: CCTTCTGCGATTCAGTGCTGT      NT 47-256          61
              R: CATACTCATTGACCCAGGGCT
Eotaxin       F: GCACGCTGAAAGCCATAGTCT      NT 204-557         61
              R: CATCTCCTTCCATGCTCTCTCCT
Rantes        F: CTGCATCCCTCACCGTCATC       NT 17-242          57
              R: CACTTCTTCTCTGGGTTGGCA
IL-10         F: AGAAGCTGAAGACCCTCTGGA      NT 385-693         59
              R: TGGAGAGAGGTACAAACGAGGT
iNOS          F: GCTCCATGACTCTCAGCACAG      NT3164-3509        57
              R: CTCAACCTGCTCCTCACTCAAG
Primers were designed using the Primer Express Program and pur-
chased from AuGCT Biotechnology, Beijing, P. R. China.
Figure 1. Phase-contrast photomicrographs of the cultured retinal microglial cells.  A: Mixed cell cultures from newborn Sprague-Dawley rats
for 14 days. B: Purified cells cultured for 48 h. Cells developed the characteristic ramified shape with a long single process and a small cell
soma (arrow). C: Purified cells stimulated with LPS for 24 h became bigger and rounder, showing an ameboid shape (arrowhead). Pretreat-
ment with minocycline D or sulforaphane E for 1 h before LPS administration partly inhibited LPS-induced microglial morphological change,
with some cells sustaining their ramified shape (arrow), but a few cells changing to an ameboid shape (arrowhead). F: Pretreatment with
SB203580 for 1 h before LPS administration completely inhibited the LPS-induced microglial morphological change, with almost all cells
sustaining their ramified shape (arrow).
1085cells showed a positive reaction for CD11b according to im-
munofluorescent studies (Figure 2A) and none of the cells
showed a positive reaction for GFAP (Figure 2C) or CRALBP
(data not shown).
Minocycline and sulforaphane inhibited lipopolysaccha-
ride-induced microglial activation:  After LPS stimulation for
24 h, the purified microglial cells became bigger and rounder
and developed the characteristic ameboid shape of activated
microglia (Figure 1C and Figure 2B). Pretreatment with
minocycline (Figure 1D) or sulforaphane (Figure 1E) for 1 h
before LPS administration partly inhibited the LPS-induced
microglial morphological change, with some cells sustaining
their ramified shape, but a few cells showed ameboid shape.
Pretreatment with SB203580 for 1 h before LPS administra-
tion completely inhibited the LPS-induced microglial morpho-
logical change (Figure 1F).
Minocycline and sulforaphane inhibited mRNA expres-
sion of inducible nitric oxide synthase and production of ni-
tric oxide in activated microglial cells:  The effect of
minocycline or sulforaphane on LPS-induced iNOS mRNA
expression and subsequent NO production in microglial cells
was investigated. The microglial cells were treated with LPS
alone or with various concentrations of minocycline or
sulforaphane. LPS induced a significant time-dependent in-
crement of nitrite and nitrate level in the culture media (Fig-
ure 3A). The increment of nitrite and nitrate levels became
significant after 6 h of LPS treatment, and continued up to 24
h. Minocycline or sulforaphane itself did not affect the basal
iNOS mRNA expression and NO production. The LPS-induced
nitrite and nitrate increment was significantly suppressed by
administration of minocycline or sulforaphane. The maximal
and most consistent inhibition was achieved by treatment with
0.01 µM to 0.625 µM minocycline, or 1.25 µM to 10 µM
sulforaphane (Figure 3B,C). The higher doses did not reduce
NO production, but had toxic effects on cells. Therefore, 0.16
µM minocycline or 5.0 µM sulforaphane were used for fol-
lowing experiments.
To further examine whether minocycline or sulforaphane
inhibited NO production via suppression of iNOS mRNA ex-
pression, the effect of minocycline or sulforaphane on iNOS
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Figure 2. Immunofluorescent characterization of the cultured retinal microglial cells.  A: The purified cells were reactive to CD11b, a cell-
type-specific marker for microglia. B: After LPS stimulation for 24 h, the CD11b-labeled cells became bigger and rounder, developing the
characteristic ameboid shape of activated microglia. C: None of the purified cells showed a positive reaction for GFAP.
Figure 3. Effect of minocycline and sulforaphane on lipopolysaccha-
ride-induced nitrite and nitrate release in cultured retinal microglial
cells.  A: Release of nitrite and nitrate from cultured retinal micro-
glia with LPS treatment. The increment of nitrite and nitrate levels
became significant after 6 h of LPS treatment and continued for up
to 24 h. B: Administration of minocycline significantly reduced LPS-
induced nitrite and nitrate production in retinal microglial cells. C:
Administration of sulforaphane significantly reduced LPS-induced
nitrite and nitrate production in retinal microglial cells. Data repre-
sented four independent experiments and were expressed as
mean±SD. Asterisk indicates p<0.01 is considered significant.
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TABLE 2. EFFECTS OF MINOCYCLINE, SULFORAPHANE OR SB203580 ON LPS-INDUCED PRODUCTION OF MCP-1, MCP-3, MIP-1Α Α Α Α Α, MIP-1Β Β Β Β Β,
EOTAXIN, RANTES, AND IL-10
          Groups                   MCP-1          MCP-3         MIP-1α      MIP-1β       eotaxin       RANTES        IL-10
-----------------------------   ------------   ------------   ----------   ----------   -----------   -----------   -----------
culture without LPS treatment   180.08±13.21   155.21±8.76    26.34±3.61   43.89±2.78   16.08±4.91     21.44±7.08    15.01±2.46
culture with LPS treatment      192.46±8.67    164.49±14.31   30.17±4.68   40.62±6.34   76.23±9.31     96.39±10.26   70.83±5.69
minocycline pretreated and      204.31±15.29   160.54±9.29    23.64±2.89   49.52±5.73   22.46±5.89*    38.61±5.37*   13.67±2.81*
   LPS-exposed culture
sulforaphane pretreated and     190.63±8.69    171.38±7.46    24.58±3.74   38.84±4.79   29.36±8.74*    34.46±3.83*   12.34±3.29*
   LPS-exposed culture
SB203580 pretreated and         176.33±10.21   150.74±8.63    26.01±2.54   36.35±4.81   19.31±4.26*    28.74±3.06*   15.73±4.87*
   LPS-exposed culture
Asterisk indicates p<0.01 was considered significant compared to the culture with LPS treatment.
Figure 4. Reverse transcriptase polymerase chain reaction analysis demonstrated the inhibitory effects of minocycline, sulforaphane and
SB203580 on lipopolysaccharide-induced mRNA expression of cytokines and inducible nitric oxide synthase in cultured retinal microglial
cells.  A: The mRNA expression of several cytokines and iNOS in cultured retinal microglial cells with or without LPS administration. The
retinal microglial cells constitutively expressed modest mRNA transcripts for MCP-1, MCP-3, MIP-1α, and MIP-1β without LPS administra-
tion, and treatment with LPS induced the upregulation of eotaxin, RANTES, IL-10 and iNOS. However, the expression levels for MCP-1,
MCP-3, MIP-1α, and MIP-1β were little changed. B: Pretreatment with minocycline, sulforaphane or SB203580 for 1 h before LPS adminis-
tration significantly reduced the LPS-induced upregulation of eotaxin, RANTES, IL-10, and iNOS, but had no significant effect on the
expression of MCP-1, MCP-3, MIP-1α, and MIP-1β.
1087mRNA expression in LPS-stimulated microglia was investi-
gated. RT-PCR analysis demonstrated that cultured microglial
cells constitutively expressed very low levels of iNOS mRNA
without LPS treatment, but expression was upregulated after
exposure to LPS (Figure 4A). LPS-induced iNOS mRNA ex-
pression was completely suppressed by treatment with
minocycline and was mostly suppressed (70%) by treatment
with sulforaphane (Figure 4B).
Minocycline and sulforaphane modulated mRNA expres-
sion and protein production of several cytokines in activated
microglial cells:  The mRNA expression of cytokines in cul-
tured retinal microglial cells with or without LPS treatment
was investigated. Retinal microglial cells without LPS admin-
istration constitutively expressed modest quantities of mRNA
transcripts for MCP-1, MCP-3, MIP-1α and MIP-1β. Follow-
ing LPS treatment, their expression was slightly upregulated,
but the difference was statistically insignificant (Figure 4A).
Retinal microglial cells without LPS treatment constitutively
expressed low levels of mRNA transcripts for eotaxin,
RANTES, and IL-10. Following LPS treatment, their expres-
sion was markedly upregulated. The expression of eotaxin and
RANTES peaked 1 h after LPS stimulation; however, the ex-
pression of IL-10 was much delayed and peaked 4 h after LPS
stimulation (Figure 4A).
Minocycline, sulforaphane or SB203580 alone did not
affect the basal mRNA transcripts for MCP-1, MCP-3, MIP-
1α, MIP-1β, eotaxin, RANTES and IL-10. Pretreatment with
minocycline, sulforaphane or SB203580 for 1 h followed by
LPS administration significantly reduced LPS-induced
upregulation of eotaxin, RANTES, and IL-10, but had no sig-
nificant effect on the expression of MCP-1, MCP-3, MIP-1α,
and MIP-1β (Figure 4B).
The protein production of MCP-1, MCP-3, MIP-1α, MIP-
1β, eotaxin, RANTES, and IL-10 in the culture media of mi-
croglial cells with or without LPS treatment was examined by
ELISA assay. Microglial cells without LPS administration
produced modest quantities of MCP-1, MCP-3, MIP-1α and
MIP-1β. Following exposure to LPS for 24 h, their produc-
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Figure 5. Western blot analysis demonstrated the inhibitory effects of minocycline, sulforaphane and SB203580 on the protein expression of
the p65 subunit of nuclear factor-κB and mitogen-activated protein kinases in cultured retinal microglial cells.  A: The protein expression of
the p65 subunit of NF-κB and p-p38, p-p44/42, and p-JNK MAPKs in cultured microglia with or without LPS administration. The cultured
retinal microglial cells constitutively expressed high levels of p-p44/42, but expressed low levels of p-p38, p-JNK, and the p65 subunit of NF-
κB without LPS administration. Following exposure to LPS, the expression of p-p38, p-JNK, and the p65 subunit of NF-κB was upregulated.
However, the expression of p-p44/42 was not changed. The ERK2 MAPK was used to assay total (phospho-independent) ERK and served as
a control to ensure that equivalent quantities of proteins were used for SDS-PAGE. B: Pretreatment with minocycline, sulforaphane or SB203580
completely inhibited LPS-induced upregulation of p-p38, but had no effect on the expression of p-p44/42, p-JNK, and the p65 subunit of NF-
κB.
1088tion was not changed. Microglial cells without LPS adminis-
tration produced low levels of eotaxin, RANTES and IL-10.
Following exposure to LPS for 24 h, their production was sig-
nificantly upregulated (Table 2).
Minocycline, sulforaphane or SB203580 alone had no
effect on the production of MCP-1, MCP-3, MIP-1α, MIP-
1β, eotaxin, RANTES, and IL-10. Pretreatment with
minocycline, sulforaphane or SB203580 for 1 h followed by
LPS administration significantly decreased LPS-induced pro-
duction of eotaxin, RANTES and IL-10 in the culture media,
but had no significant effect on the production of MCP-1,
MCP-3, MIP-1α, and MIP-1β (Table 2).
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Figure 6. Immunofluorescent
localization of the p65 subunit
of nuclear factor-κB and the p-
p38, and p-JNK mitogen-acti-
vated protein kinases in cul-
tured retinal microglial cells.
A: Cells expressed very low
levels of the p65 subunit of NF-
κB without LPS administra-
tion. B: Following exposure to
LPS for 1 h, p65 subunit label-
ing was upregulated and trans-
located into the nuclei (arrow).
C: Cells expressed low levels
of p-p38 without LPS admin-
istration. D: Following expo-
sure to LPS for 1 h, p-p38 ex-
pression was upregulated and
positive labeing was present in
both cytoplasm (arrow) and
nuclei (arrowhead). E: Retinal
microglial cells expressed low
levels of p-JNK without LPS
administration. F: Following
exposure to LPS for 1 h, the
positive labeling of p-JNK was
present mainly in nuclei (ar-
rowhead). Pretreatment with
minocycline G or sulforaphane
H for 1 h followed by LPS ad-
ministration completely inhib-
ited LPS-induced upregulation
of p-p38. All panels have the
same scale and the scale bar
equal to 8 µm.
1089The inhibitory effects of minocycline and sulforaphane
were associated with the p38 mitogen-activated protein ki-
nases pathway in activated microglial cells:  To examine
whether minocycline or sulforaphane inhibit LPS-induced
microglial activation via the NF-κB or MAPK pathway, the
protein expression of the p65 subunit of NF-κB and the p-
p38, p-p44/42, and p-JNK MAPKs in microglial cells with or
without minocycline and sulforaphane treatment were inves-
tigated. Retinal microglial cells expressed low levels of the
p65 subunit of NF-κB without LPS treatment, but expression
was upregulated after stimulation with LPS. The p65 subunit
was activated within 20 min after LPS stimulation, reached
its peak at 30 min, and persisted at this level for least to 2 h.
Without LPS treatment, the cells constitutively expressed high
levels of p-p44/42, but expressed very low levels of p-p38
and p-JNK. An induced upregulation of p-p38 and p-JNK was
demonstrated after stimulation with LPS, but the expression
level for p-p44/42 was not changed. The p-p38 MAPK was
activated within 20 min after LPS stimulation, started to de-
cline after 1 h, and decreased back to basal levels within 2 h.
P-JNK was activated within 20 min after LPS stimulation,
reached its peak at 30 min, and persisted at this level for at
least to 2 h (Figure 5A).
Pretreatment with minocycline or sulforaphane for 1 h
followed by LPS administration completely inhibited the LPS-
induced upregulation of p-p38, but had no effect on the ex-
pression of p-p44/42, p-JNK, and the p65 subunit of NF-κB
(Figure 5B).
Immunofluorescent studies:  To further confirm the
upregulation of p-p38, p-JNK, and the p65 subunit of NF-κB
in LPS-stimulated microglial cells, protein levels were stud-
ied with immunofluorescence. Retinal microglial cells ex-
pressed very low levels of the p65 subunit of NF-κB without
LPS administration (Figure 6A). Following LPS administra-
tion for 1 h, p65 subunit labeling was upregulated and translo-
cated into nuclei (Figure 6B). Similarly, cells expressed low
levels of p-p38 without LPS administration (Figure 6C). Fol-
lowing LPS administration for 1 h, p-p38 labeling was
upregulated and positive labeling was present in both cyto-
plasm and nuclei (Figure 6D). Cells expressed low levels of
p-JNK without LPS administration (Figure 6E), but labeling
was upregulated following LPS administration for 1 h and was
present mainly in the nuclei (Figure 6F). Pretreatment with
minocycline (Figure 6G) or sulforaphane (Figure 6H) for 1 h
followed by LPS administration completely inhibited LPS-
induced upregulation of p-p38, but had no effect on the ex-
pression of p-JNK and the p65 subunit of NF-κB (data not
shown).
DISCUSSION
 Our study demonstrated (1) the expression of 8 immunologi-
cal signaling molecules (chemokines and noxious factors) in
cultured retinal microglial cells treated with or without LPS;
(2) that NF-κB and MAPKs were two cellular pathways in-
volved in LPS-mediated microglial activation processes; and
(3) that minocycline and sulforaphane had efficient inhibitory
effects on LPS-mediated microglial activation processes, partly
through a p38 MAPK-dependent mechanism.
In the present study, the cultured retinal microglial cells
changed their morphological shape following LPS adminis-
tration (Figure 1B,C). The mRNA expression of iNOS and
subsequent production of NO were upregulated (Figure 4A
and Figure 3A), as was mRNA expression of pro-inflamma-
tory cytokines including eotaxin, RANTES and IL-10. How-
ever, mRNA expression of the chemokines MCP-1, MCP-3,
MIP-1α, and MIP-1β was not significantly changed (Figure
4A).
Microglial activation and the associated induction of NO
and pro-inflammatory cytokines have been well documented
in various neurodegenerative diseases, such as Alzheimer’s
disease and Parkinson’s disease [21,22]. NO seemed to play
an important role in the pathogenesis of endotoxin-induced
uveitis [23] and light-induced retinal degeneration [24]. In the
present study, we observed that iNOS mRNA expression and
subsequent NO production were upregulated in retinal micro-
glia after LPS treatment, suggested that NO may be an impor-
tant mediator of the neurotoxic activity exerted by activated
retinal microglial cells.
Chemokines and cytokines are immune signaling mol-
ecules that may inflict secondary damage during inflamma-
tion and exaggerate neurodegeneration [25,26]. Resting mi-
croglia are dominant immune surveillant cells which need
appropriate stimulation to be transformed into full-blown
macrophages [1,27]. The activation process included the syn-
thesis of cytotoxic substances such as oxygen radicals, nitric
oxide, proteases, and proinflammatory cytokines [28,29].
Eotaxin and RANTES are members of the C-C chemokine
family, which were involved in macrophage recruitment dur-
ing inflammation [30]. Therefore, the upregulated expression
of eotaxin and RANTES in retinal microglia following LPS
treatment might be important for the propagation and mainte-
nance of the retinal immune response or for recruitment of
more microglia to the lesion. Previous in vivo studies from
Zeng et al. [5] demonstrated that normal retinas containing
resting microglia do not expressed MCP-1, MCP-3, MIP-1α,
and MIP-1β. However, their expression was upregulated in
retinal degeneration. In the present study, we demonstrated
that the cultured retinal microglial cells without LPS treat-
ment constitutively expressed modest quantities of MCP-1,
MCP-3, MIP-1α, and MIP-1β, and their expression was little
changed after LPS treatment. This might be because cultured
microglial cells in vitro exhibit a reactive phenotype and pro-
duce cytokines that are specific for reactive microglia [31].
The constitutively expressed chemokines in these cells might
be due to the preparation procedure for the culture. Further in
vivo studies are needed to illustrate their role in retinal dis-
ease.
It is accepted that the production of pro-inflammatory
cytokines in the CNS is under strict control to maintain nor-
mal homeostasis of the CNS. We demonstrated that retinal
microglial cells also secreted the anti-inflammatory cytokine
IL-10 after LPS treatment, which suppressed the activated
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nal microglial cells play an important role in the propagation
and maintenance of the retinal immune response. The
upregulation of several chemokines in retinal microglial cells
following treatment with LPS suggested the involvement of
complicated immunological mechanisms in the retinal disease
process.
In this study, LPS treatment upregulated the expression
of the p65 subunit of NF-κB and the p-p38 and p-JNK MAPKs,
but did not change the high levels of p-p44/42 MAPK expres-
sion (Figure 5 and Figure 6). NF-κB is a ubiquitous transcrip-
tion factor that regulates a broad range of genes and is a cen-
tral regulator of microglial response to activating stimuli, in-
cluding LPS and cytokines [32]. One previous study demon-
strated that, upon stimulation, IκB phosphorylation and deg-
radation allowed NF-κB to translocate into the nucleus and
recognize consensus sequences in target genes, including
iNOS, IL-1β, and TNF-α [33]. Consistent with this finding,
our observation demonstrated that the NF-κB pathway played
a role in the LPS-induced retinal microglial activation pro-
cess.
MAPKs are serine/threonine kinases and form one of the
major pathways linking extracellular stimuli to transcriptional
activation and gene expression. The p-p38 MAPK pathway is
involved in the induction of several pro-inflammatory genes
and p-p38 and p-JNK are always activated simultaneously [34].
In this study, we demonstrated that LPS stimulation induced
the upregulation of p-p38 and p-JNK in retinal microglial cells,
and p-p38 and p-JNK were activated simultaneously.
SB203580, a specific inhibitor of p-p38, inhibited the LPS-
induced retinal microglial morphological change and modu-
lated cytokine expression. We suggested that the activation of
p-p38 in retinal microglia by LPS is the first step in initiating
the inflammatory process, resulting in the production of su-
peroxide radicals and cytokines, which further stimulate the
inflammatory response. The studies of Fukuda et al. [35] and
Robinson et al. [36] showed that a constitutively active and
nuclear form of p44/42 was sufficient for neurite outgrowth
and cell transformation, and up to 80% of prostate cells in the
stroma and basal layers stained positively for p-p44/42 within
the nucleus [37]. In contrast, Combs et al. [38] argued that p-
p44/42 might play a critical role in harmful microglial activa-
tion in acute brain injury, such as stroke, and in more chronic
neurodegenerative disease, such as Alzheimer’s disease. Our
observations demonstrated that p-p44/42 was constitutively
expressed in cultured retinal microglial cells without LPS ad-
ministration. LPS administration did not alter its activity, sug-
gesting that p44/42 does not play an important role in micro-
glial activation in retinal disease.
Studies by Tang et al. [39] and Liu et al. [40] showed that
the MAPK and NF-κB pathways, which were almost invari-
ably co-activated by cytokines and stress, were intimately
linked. One of the major molecules for p65 phosphorylation
and transactivation appeared to be p-p38 [41]. Saccani et al.
[42] also suggested that p-p38 further enhances NF-κB sig-
naling via direct modification of histone proteins in the cryp-
tic κB-regulatory element. In the present study, we demon-
strated that SB203580 had no effect on the expression of p-
p44/42, p-JNK, and the p65 subunit of NF-κB. It might be
that the cellular pathways of NF-κB and MAPKs are rela-
tively separate in LPS-induced microglial activation.
Minocycline was an anti-inflammatory agent which was
used in the management of inflammatory and degenerative
disease. It was shown to inhibit retinal microglial activation
and migration in photic injury. Being a second-generation,
semi-synthetic tetracycline with broad-spectrum antimicrobial
activity, minocycline was shown to exert biological effects
completely distinctive from tetracycline [43]. The mechanism
by which minocycline suppressed LPS-induced activation of
microglia is not clearly understood, but might be relate to the
anti-inflammatory effect and inhibitory effect on microglial
activation and migration. In contrast, sulforaphane inhibited
phase enzymes such as cytochrome P450 and induces phase
detoxification enzymes [44-46]. Intraperitoneal pretreatment
with sulforaphane was found to attenuate light-induced reti-
nal damage via an antioxidant-responsive element/thioredoxin
signaling cascade [47]. It also suppressed inflammatory reac-
tion in macrophage[17]. In this study, pre-treatment with
minocycline or sulforaphane followed by LPS administration
inhibited LPS-induced microglial morphological change and
decreased mRNA expression of iNOS and subsequent NO
production. They also inhibited LPS-induced upregulation of
p-p38, but had no significant effect on the expression of p-
p44/42, p-JNK, and the p65 subunit of NF-κB. Banati et al.
[29] proposed that activated microglia exert cytotoxic effects
in the brain through two very different yet complementary
processes. First, they act as phagocytic cells, which involves
direct cell-to-cell contact. Second, they are capable of releas-
ing a large variety of potentially harmful substances. Our study
suggested that the inhibitory effect of minocycline and
sulforaphane on LPS-induced microglial activation suppressed
the phagocytic activity and decreased the expression of in-
flammatory mediators. This inhibitory effect was associated
with a p38-dependent pathway.
In conclusion, our study demonstrated that minocycline
and sulforaphane inhibited LPS-induced retinal microglial ac-
tivation, western blot and immunofluorescent studies showed
decreased p-p38 MAPK expression. We suggested that the in-
hibitory effect of minocycline and sulforaphane was partly
through a p38 MAPK-dependent mechanism. Given the fact
that microglial activation contributes to the pathogenesis of
several retinal disorders, minocycline or sulforaphane may be
potential therapeutic agents for inflammatory or degenerative
retinal diseases.
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